Yayın:
Evaluation of Hepatitis A Seroprevalence in Kastamonu Province, Turkey

dc.contributor.authorTÜFEKCİ, Enis Fuat
dc.contributor.authorÇALIŞIR, Büşra
dc.contributor.authorYAŞAR DUMAN, Melike
dc.contributor.authorKILINÇ, Çetin
dc.date.accessioned2026-01-04T17:15:46Z
dc.date.issued2022-09-22
dc.description.abstractAim: Hepatitis A disease is a contagious liver infection caused by the hepatitis A virus (HAV). This study aimed to decide the hepatitis A seroprevalence in all age groups in Kastamonu province, Turkey. Material and Method: The current study analyzed the anti-HAV antibodies test results of the patients who applied to Kastamonu Training and Research Hospital for various reasons between 2018-2022. The most up-to-date test results of patients sent more than one serum sample were evaluated. The patients were separated into eight age groups: 0-10,11-20, 21-30, 31-40, 41-50, 51-60, 61-70, and ≥71. The anti-HAV IgM and anti-HAV IgG values were determined using the chemiluminescence microparticle immunoassay method in the Abbott Architect i2000SR. The results were evaluated based on the manufacturer’s instructions. Results: There was positivity in 27 (1.3%) of 2083 patients in whom anti-HAV IgM was studied and in 837 (58.2%) of 1439 patients in whom anti-HAV IgG was studied. The anti-HAV IgG positivity in females and males was 55.9% and 61.0%, respectively; anti-HAV IgM positivity was 1.7% and 0.8%. The anti-HAV IgG positivity rate increased with increasing age (p
dc.description.urihttps://doi.org/10.37990/medr.1116309
dc.identifier.doi10.37990/medr.1116309
dc.identifier.eissn2687-4555
dc.identifier.endpage432
dc.identifier.openairedoi_dedup___::8b95ab3fb5ee5db953bde24bfaedf0e0
dc.identifier.orcid0000-0001-5051-2694
dc.identifier.orcid0000-0001-6257-5422
dc.identifier.orcid0000-0001-8913-2314
dc.identifier.orcid0000-0003-4958-2622
dc.identifier.startpage428
dc.identifier.urihttps://hdl.handle.net/20.500.12597/40005
dc.identifier.volume4
dc.publisherMedical Records - International Medical Journal
dc.relation.ispartofMedical Records
dc.rightsOPEN
dc.subject.sdg3. Good health
dc.titleEvaluation of Hepatitis A Seroprevalence in Kastamonu Province, Turkey
dc.typeArticle
dspace.entity.typePublication
local.api.response{"authors":[{"fullName":"Enis Fuat TÜFEKCİ","name":"Enis Fuat","surname":"TÜFEKCİ","rank":1,"pid":{"id":{"scheme":"orcid","value":"0000-0001-5051-2694"},"provenance":null}},{"fullName":"Büşra ÇALIŞIR","name":"Büşra","surname":"ÇALIŞIR","rank":2,"pid":{"id":{"scheme":"orcid","value":"0000-0001-6257-5422"},"provenance":null}},{"fullName":"Melike YAŞAR DUMAN","name":"Melike","surname":"YAŞAR DUMAN","rank":3,"pid":{"id":{"scheme":"orcid","value":"0000-0001-8913-2314"},"provenance":null}},{"fullName":"Çetin KILINÇ","name":"Çetin","surname":"KILINÇ","rank":4,"pid":{"id":{"scheme":"orcid","value":"0000-0003-4958-2622"},"provenance":null}}],"openAccessColor":"gold","publiclyFunded":false,"type":"publication","language":{"code":"und","label":"Undetermined"},"countries":null,"subjects":[{"subject":{"scheme":"FOS","value":"0301 basic medicine"},"provenance":null},{"subject":{"scheme":"FOS","value":"03 medical and health sciences"},"provenance":null},{"subject":{"scheme":"FOS","value":"0302 clinical medicine"},"provenance":null},{"subject":{"scheme":"SDG","value":"3. Good health"},"provenance":null}],"mainTitle":"Evaluation of Hepatitis A Seroprevalence in Kastamonu Province, Turkey","subTitle":null,"descriptions":["<jats:p xml:lang=\"en\">Aim: Hepatitis A disease is a contagious liver infection caused by the hepatitis A virus (HAV). This study aimed to decide the hepatitis A seroprevalence in all age groups in Kastamonu province, Turkey. Material and Method: The current study analyzed the anti-HAV antibodies test results of the patients who applied to Kastamonu Training and Research Hospital for various reasons between 2018-2022. The most up-to-date test results of patients sent more than one serum sample were evaluated. The patients were separated into eight age groups: 0-10,11-20, 21-30, 31-40, 41-50, 51-60, 61-70, and ≥71. The anti-HAV IgM and anti-HAV IgG values were determined using the chemiluminescence microparticle immunoassay method in the Abbott Architect i2000SR. The results were evaluated based on the manufacturer’s instructions. Results: There was positivity in 27 (1.3%) of 2083 patients in whom anti-HAV IgM was studied and in 837 (58.2%) of 1439 patients in whom anti-HAV IgG was studied. The anti-HAV IgG positivity in females and males was 55.9% and 61.0%, respectively; anti-HAV IgM positivity was 1.7% and 0.8%. The anti-HAV IgG positivity rate increased with increasing age (p</jats:p>"],"publicationDate":"2022-09-22","publisher":"Medical Records - International Medical Journal","embargoEndDate":null,"sources":["Crossref"],"formats":null,"contributors":null,"coverages":null,"bestAccessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":{"name":"Medical Records","issnPrinted":null,"issnOnline":"2687-4555","issnLinking":null,"ep":"432","iss":null,"sp":"428","vol":"4","edition":null,"conferencePlace":null,"conferenceDate":null},"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"doi_dedup___::8b95ab3fb5ee5db953bde24bfaedf0e0","originalIds":["10.37990/medr.1116309","50|doiboost____|8b95ab3fb5ee5db953bde24bfaedf0e0"],"pids":[{"scheme":"doi","value":"10.37990/medr.1116309"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":2,"influence":2.6690752e-9,"popularity":3.4327359e-9,"impulse":2,"citationClass":"C5","influenceClass":"C5","impulseClass":"C5","popularityClass":"C5"}},"instances":[{"pids":[{"scheme":"doi","value":"10.37990/medr.1116309"}],"type":"Article","urls":["https://doi.org/10.37990/medr.1116309"],"publicationDate":"2022-09-22","refereed":"peerReviewed"}],"isGreen":false,"isInDiamondJournal":false}
local.import.sourceOpenAire

Dosyalar

Koleksiyonlar